MLPA is a ligation-dependent PCR method that quantifies up to 50 genomic targets in a single reaction. Its core design relies on two adjacent oligonucleotide probes per target that are ligated only when perfectly hybridized, followed by universal PCR amplification of all ligated probes and capillary electrophoresis to resolve them by size. This elegantly transforms copy-number analysis into a relative peak-area comparison, making MLPA a workhorse for detecting exon deletions, duplications, and gene copy-number variations (CNVs) in diagnostic workflows.
MLPA’s power comes from dual-probe ligation for exquisite specificity and universal PCR for unbiased amplification—but its standard format detects only copy-number changes, not single-nucleotide variants. Understanding this trade-off is essential for designing robust, clinically accurate tests.
The Dual-Probe Architecture: Ligation as the Gatekeeper of Specificity
The assay’s precision starts at the molecular level. Each target locus is interrogated by two probes that must hybridize immediately adjacent to one another.
How Perfect-Match Hybridization Drives Ligation
DNA ligase covalently joins the probes only if both are perfectly base-paired to the target. A single mismatch at the ligation junction drastically reduces ligation efficiency, giving MLPA its allele-discrimination power. This gatekeeping step ensures that only the intended genomic sequences generate amplifiable product.
The Role of Stuffer Sequences in Multiplex Distinction
Each probe pair contains not only the target-specific region but also a unique, non-hybridizing “stuffer” tail of variable length. After ligation, these tails become part of the PCR amplicon, creating a library of products with distinct sizes. Careful length design—spanning a typical range of 130–490 bp—allows up to 50 targets to be resolved in a single capillary run.
Universal PCR: Eliminating Amplification Bias Across Targets
Traditional multiplex PCR suffers from differential primer efficiencies. MLPA sidesteps this entirely with a single common primer pair.
One Primer Set to Amplify All Ligated Probes
Every probe incorporates universal primer binding sites flanking the target-specific sequences. Post-ligation, only probes that have been covalently joined become full templates. A single fluorescently labeled primer pair amplifies all ligated species with identical reaction kinetics, so the relative abundance of each amplicon faithfully reflects the starting copy number.
Why This Matters for Quantification
Because all targets share the same amplification context, peak ratios remain stable across PCR cycles. This eliminates the need for complex normalization for primer efficiency and allows direct comparison between a test sample and a reference sample within the same run.
Readout by Capillary Electrophoresis: Translating Size into Signal
The final step converts the physical amplicon mixture into digital copy-number calls.
Converting Amplicon Length into Distinct Peaks
Amplicons are injected into a capillary, separated by size, and detected via the fluorescent label. Each target appears as a single peak in an electropherogram, with peak height or area proportional to the amount of ligated probe—and thus to the target’s copy number.
Relative Quantification Through Peak Comparison
In diagnostic CNV analysis, a sample’s peak areas are normalised against those from a reference sample with known copy numbers. A 50% reduction in a peak area relative to the reference signals a heterozygous deletion; a 150% increase indicates a duplication. This relative-quantification strategy delivers the high precision needed for clinical exon-level copy-number calls.
Understanding the Limitations and Critical Trade-offs
No technique is universal, and MLPA’s strengths come with clear boundaries that diagnostic developers must navigate.
Standard MLPA Is Blind to Point Mutations
The ligation‑centric design excels at copy‑number changes but fails to detect single‑nucleotide variants (SNVs) or small indels unless special “mutation‑specific” probes are added. For example, standard MLPA for Spinal Muscular Atrophy (SMA) reliably identifies SMN1 exon 7 deletions but will miss rare SMA cases caused by intragenic point mutations—a critical gap that can lead to false‑negative carrier assessments.
Probe Design and Quality Dictate Success
The entire assay depends on high‑purity synthetic probes with precisely engineered stuffer lengths. Poor oligonucleotide quality or incomplete ligation can generate spurious peaks or signal drift. Robust DNA ligase enzymes and fluorescent primers with consistent labelling are non‑negotiable for reproducible results.
Multiplex Breadth Has a Ceiling
While MLPA can theoretically quantify up to 50 targets, practical multiplexing is bounded by the size‑separation window of capillary electrophoresis and the need to avoid peak overlap. Crowding the size range increases the risk of co‑migrating products and compromises accurate peak calling.
Making the Right Choice for Your Diagnostic Goal
Deploying MLPA effectively means aligning its capabilities with your specific clinical application.
- If your primary focus is high‑multiplex, cost‑effective CNV screening for large gene panels: Leverage MLPA’s ability to interrogate up to 50 targets in a single tube. Invest heavily in probe design optimization and use a well‑characterized reference sample for every run.
- If your clinical application requires detection of all mutation types, including point mutations: Implement a multi‑tiered testing protocol. Use MLPA for initial CNV assessment, then reflex to a complementary sequencing panel or include additional mutation‑specific probes to cover SNV‑driven disease.
- If you are developing an IVD kit for a well‑defined disorder with known deletion/duplication hotspots: Exploit the universal PCR framework to simplify manufacturing and reduce lot‑to‑lot variability. Validate each probe batch with synthetic reference standards and confirm ligation efficiency under stringent conditions.
When you understand both the elegant mechanics and the inherent trade‑offs, MLPA becomes a precise, scalable, and cost‑efficient engine for copy‑number diagnostics—one that you can confidently deploy as a foundational layer in your molecular testing strategy.
Summary Table:
| MLPA Stage | Key Assay Mechanism | Clinical & Technical Impact |
|---|---|---|
| Dual-Probe Ligation | Probes hybridize adjacently; ligase joins them only upon a perfect match. | Delivers high specificity for CNVs; blind to SNVs/point mutations. |
| Stuffer Sequences | Variable-length tails (130–490 bp) added to each probe pair. | Enables single-tube multiplex resolution of up to 50 genomic targets. |
| Universal PCR | A single fluorescent primer set amplifies all ligated species identically. | Eliminates amplification bias; preserves initial copy-number ratios. |
| Capillary Readout | Amplicons separated by size; peak area normalized against a reference. | Translates relative peak areas into precise deletion/duplication calls. |
Advance Your Diagnostic Assay Development with CamelBio
Developing high-precision MLPA panels and multiplex diagnostic assays requires flawless raw materials and reliable assay design. CamelBio provides diagnostic manufacturers, clinical laboratories, and research institutes with one-stop access to premium IVD raw materials, specialized technical services, and expert consulting—supporting your development pipeline every step from concept to clinic.
Whether you require high-purity enzymes, custom probe support, or optimization consulting, CamelBio is your trusted partner for clinical-grade diagnostic solutions.
👉 Contact CamelBio Today to request samples or consult with our IVD technical experts!